<DOC>
	<DOCNO>NCT01957852</DOCNO>
	<brief_summary>Introduction Modern treatment peritoneal carcinomatosis ( PC ) combine aggressive cytoreductive surgery ( CRS ) macroscopic disease hyperthermic intraperitoneal chemotherapy ( HIPEC ) perform time surgery . It consider high risk procedure post-operative intra-abdominal bleeding major issue delay recovery promote intra-abdominal infection . In severe case ( 10 20 % patient ) , second surgery control bleed necessary . Major cause bleed : radical resection , extensive peritonectomy , length surgery , massive transfusion use HIPEC . To reduce risk intra-abdominal hemorrhage , many strategy try one liberal use FloSeal , data particular field interest . Over last 18 month , investigator start use FloSeal case large PC observe dramatic reduction rate reoperation bleeding probably secondarily , use blood product , measure . Hypothesis FloSeal reduce risk bleed CRS HIPEC procedure . Primary objective To evaluate use FloSeal reduce risk reoperation CRS HIPEC procedure treatment PC . Secondary objective - To evaluate use FloSeal reduce operative blood loss . - To evaluate use FloSeal reduce need blood product CRS HIPEC procedure . - To evaluate use FloSeal impact common surgical complication ( indirectly bleed relate ) . - To evaluate use FloSeal impact length hospital stay .</brief_summary>
	<brief_title>FloSeal CRS HIPEC</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<criteria>Male female patient older 18 year old All case PC regardless primary tumour ( colorectal carcinoma , peritoneal mesothelioma , appendiceal carcinoma etc . ) Prophylactic HIPEC Peritoneal Carcinomatosis Index ( PCI ) &lt; 5</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>